Through the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE), the Personalized Health Care Initiative sponsored a workshop in Washington, D.C., on July 7, 2008 entitled “Understanding the Needs of Consumers in the Use of Genome-based Health Information Services.
Office of Science and Data Policy (SDP)
The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.
The Office of Science and Data Policy includes several components:
- Division of Science and Public Health Policy
- Division of Evidence, Evaluation and Data Policy
- Division of Strategic Planning
Topic Areas:
- HHS Data Council
- Regulatory Impact Analysis
- Strategic Planning
- Information Quality Guidelines
- Prevention and wellness
- Public health systems and functions
- Food safety and nutrition
- Drugs and devices
- Tobacco control and prevention
- Biomedical research and development
- Economic analysis
- Emergency preparedness, response, and recovery
- Data and statistical policy
- Health disparities and vulnerable populations
- Health information technology
- Microsimulation
- Privacy policy
Reports
Displaying 151 - 160 of 179. 10 per page. Page 16.
Advanced SearchNationwide Health Information Network (NHIN) Workforce Study: Final Report
Submitted to Assistant Secretary for Planning and Evaluation Office of the Secretary U.S. Department of Health and Human Services Washington, DC Submitted by: Altarum Institute Ann Arbor, MI and NHII Advisors Arlington, VA
Personalized Health Care Expert Panel Meeting: Summary Report
Contents Demonstrating Clinical Validity and Utility Demonstrating Value Reducing Health Disparities Educating and Engaging Providers and Consumers Using Databases to Build Eviden
Consumer Control of Electronic Personal Health Information: What Does It Mean? Why Is It Important?
A Report on Three Consumer Focus Group Meetings Convened in October, 2005 by the Office of the Assistant Secretary for Planning and Evaluation By: Susan Kanaan Suzie Burke-Bebee Helga E. Rippen U.S. Department of Health and Human Services
Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)
Contents IGIV Supply and Distribution - Key Findings IGIV Demand - Key Fundings IGIV Access Problems- Key Fundings Immune globulin intravenous (IGIV), also referred to as intravenous immune globulin (IVIG), is a valuable treatment for many seriously ill patients. Although the U.S.
Cost Effectiveness Considerations in the Approval and Adoption of New Health Technologies
Contents Background and Purpose Methodology Summary of Key Findings and Stakeholder Suggestions Conclusions and Policy Implications A.
Assessing the Economics of EMR Adoption and Successful Implementation in Physician Small Practice Settings
By: Moshman Associates, Booz, Allen, Hamilton This report is currently only available in PDF format.